Investigating how certain proteins affect blood flow blockages in sickle cell disease
Official title: Oxidative Cysteine Modification by Thiol Isomerases in Sickle Cell Disease
Funded at Bloodworks · NIH-11127027 · Data updated 2026-11-12
This study is looking at how certain proteins might cause painful blockages in blood vessels for people with sickle cell disease, with the hope of finding new ways to help reduce these painful episodes.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Bloodworks NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $249,000 |
| NIH project number | 4R00HL164888-03 |
| Project ID | NIH-11127027 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with sickle cell disease who experience recurrent vaso-occlusive crises.
✕Less likely to help
Patients without a diagnosis of sickle cell disease or those who do not experience vaso-occlusive events may not benefit from this research.
What this research studies
This research focuses on understanding the role of thiol isomerases, a type of protein, in causing vaso-occlusive events in sickle cell disease (SCD). These events are painful blockages in blood vessels that can occur despite existing treatments. The study aims to explore how oxidative stress and specific proteins contribute to these blockages, potentially leading to new treatment strategies. By examining the interactions of these proteins in the body, the research seeks to identify ways to reduce the frequency and severity of vaso-occlusive crises in patients with SCD.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly reduce painful vaso-occlusive events in patients with sickle cell disease.
How similar studies have gone: Previous research has shown promise in targeting oxidative stress and related proteins in sickle cell disease, indicating that this approach may lead to meaningful advancements.
Where this research is happening
-
Bloodworks
Seattle, United States Active
Researchers
- Principal investigator: Yang, Moua — Bloodworks
- Study coordinator: Yang, Moua
Related research
Other NIH-funded projects on the same topics.
-
Digital twins of the spleen to help design better therapies for sickle cell disease
A computer-driven replica of the spleen is being developed to speed up creating safer and more effective treatments for people with sickle cell disease.
-
Accelerating hydroxyurea use for sickle cell disease in Nigeria
A pragmatic study in Nigeria aims to help doctors use hydroxyurea more consistently for people with sickle cell disease.
-
Immune and nerve signals behind acupuncture relief for sickle cell pain
This NIH grant explores how acupuncture helps reduce pain and opioid use for people with sickle cell disease.
-
Mindfulness-based Support for Pain and Sleep in Young People with Sickle Cell Disease
A digital mindfulness program is being tailored for adolescents and young adults with sickle cell disease to help with pain and sleep and is being tested for practicality and early effectiveness.
-
How diet affects white blood cells and sickle cell disease
A study looks at how nutrition, from early life to adulthood, influences sickle cell disease by examining neutrophils and disease severity in people with SCD and in a mouse model.
-
Nutrition-based plan to ease pain in sickle cell disease
A nutrition-based approach is being tested to reduce pain for people living with sickle cell disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.